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Abstract
Background: Fibromyalgia (FM) is a chronic, centralized pain condition characterized by alterations in the functional,
chemical, and structural brain networks responsible for sensory and mood processing. Transcranial direct current
stimulation (tDCS) has emerged as a potential treatment for FM. tDCS can alter functional connectivity (FC) in brain
regions underneath and distant to the stimulating electrode, although the analgesic mechanisms of repetitive tDCS
remain unknown. The aim of this study was to investigate how a clinically relevant schedule of tDCS sessions alters
resting state FC and how these changes might relate to clinical pain.
Methods: Resting state functional magnetic resonance imaging data were collected from 12 patients with FM at
baseline, after 5 days of sham treatment, and after 5 days of real tDCS with the anode over the left primary motor
cortex (M1) and the cathode over the right supraorbital cortex. Seed to whole-brain FC analyses were performed with
seed regions placed in bilateral M1, primary somatosensory cortices (S1), ventral lateral (VL) and ventral posterolateral
(VPL) thalami, and periaqueductal gray (PAG).
Results: Stronger baseline FC between M1–VL thalamus, S1–anterior insula, and VL thalamus–PAG predicted greater
analgesia after sham and real tDCS. Sham treatment (compared with baseline) reduced FC between the VPL thalamus,
S1, and the amygdala. Real tDCS (compared with sham treatment) reduced FC between the VL thalamus, medial
prefrontal, and supplementary motor cortices. Interestingly, decreased FC between the VL/VPL thalamus and posterior
insula, M1, and S1 correlated with reductions in clinical pain after both sham and active treatments.
Conclusions: These results suggest that while there may be a placebo response common to both sham and real tDCS,
repetitive M1 tDCS causes distinct changes in FC that last beyond the stimulation period and may produce analgesia
by altering thalamic connectivity.
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Background
Fibromyalgia (FM) is a chronic centralized pain condition
characterized by widespread pain, fatigue, sleep problems,
cognitive dysfunction, and mood disturbances [1]. While
the exact pathophysiology of FM remains unknown, a
prevailing hypothesis states that a sensory processing
dysfunction within the central nervous system creates,
amplifies, or sustains the perception of chronic pain [2].
In support of this hypothesis, brain network alterations
seen in these patients fall into two broad categories: de-
creased descending antinociceptive transmission, and/or
enhanced pronociceptive processing [3–6].
Motor cortical dysfunction has been suggested in a
number of chronic pain conditions, including FM. In
general, the primary motor cortex (M1) shows increased
cortical excitability at baseline and heightened responses
to sensory stimuli, which may be suggestive of a reduc-
tion in inhibitory activity [7]. Noninvasive brain stimula-
tion has emerged as an attractive therapeutic option for
chronic pain conditions, given its ability to target spe-
cific cortical regions. Researchers in some studies have
reported that transcranial direct current stimulation
(tDCS) over M1 relieves pain in FM [8–10]. However,
the authors of a recent review did not find a significant
difference between sham and real M1 tDCS on short-
term pain relief [11]. The lack of effect may be due to
significant heterogeneity between the studies (i.e., stimu-
lation parameters, number of treatment sessions, type of
chronic pain) included in the review. It is also possible
that sham tDCS produces a significant placebo response.
Consistent with previous work implicating the endogen-
ous opioid system in placebo analgesia [12, 13], we
recently showed that sham tDCS caused the release of
endogenous opioids in the periaqueductal gray (PAG),
precuneus, and thalamus [14].
While placebo responses are clearly present in tDCS,
the specific neurobiology underlying the analgesic effects
of real tDCS are less clear. During and immediately after
stimulation, tDCS may alter excitability by modulating
resting membrane potential. Longer-lasting effects may
be due to changes in synaptic plasticity via mechanisms
similar to long-term potentiation or depression [15]. M1
tDCS can alter the functional connectivity (FC) of re-
gions under the stimulating electrode [16], as well as
spatially distant but structurally connected regions, such
as the thalamus [17] and dorsolateral prefrontal cortex
[18, 19]. Real tDCS also acts on the endogenous opioid
system [14] similarly to invasive motor cortex stimula-
tion (MCS) [20, 21]. However, these studies were con-
ducted in healthy participants and the investigators
examined FC during or shortly after M1 tDCS. There
have been no investigations of how M1 tDCS alters
resting state FC in patients with chronic pain treated
repeatedly, as they might be in clinical practice.
We measured clinical pain and resting state FC in 12
patients with FM at baseline, after 5 days of sham treat-
ment, and after 5 days of real tDCS. We were interested
in three questions: (1) Does baseline connectivity predict
clinical treatment response? (2) Are there differences in
FC after sham and real tDCS? (3) Do changes in FC relate
to analgesia? We hypothesized that strong M1–thalamus
connectivity at baseline would predict a better clinical
response, as shown in previous M1 stimulation studies
[22, 23]. In addition, because we found a trend toward
decreased glutamate + glutamine (Glx) in the thalamus
after real tDCS in these same patients [24], and given the
strong structural connectivity between M1 and the
thalamus [25], we hypothesized that real tDCS would
decrease FC between the thalamus and brain regions
involved in pain perception.
Methods
Patients
We recruited 13 female patients with FM (age range
27–64 years, mean ± standard deviation 47.6 ± 10.6 years)
for this study. One patient dropped out after the baseline
visit, and the remaining twelve patients completed the en-
tire protocol. All patients met the 1990 American College
of Rheumatology criteria for FM [1], had experienced
symptoms for at least 1 year, and reported pain on more
than 50 % of days. The inclusion criteria were right-
handed, a body mass index of 36 or less, and agreement to
delay taking new medications or treatments for FM during
the study. The exclusion criteria were pregnant or breast-
feeding, participation in other clinical trials, currently
taking opiates, history of autoimmune or chronic inflam-
matory disease that causes pain, substance abuse or severe
psychiatric illness, and contraindications for magnetic res-
onance imaging procedures. The University of Michigan
Institutional Review Board approved this study, and all
subjects gave written informed consent. The effect of
tDCS on brain metabolites in these same subjects is
described in a previous report [24].
Study design
Our within-subjects crossover design had three phases
(Additional file 1: Figure S1). Session 1 included a base-
line pain assessment and functional magnetic resonance
imaging (fMRI). Session 2 consisted of sham tDCS for 5
consecutive days followed by pain assessment and a sec-
ond fMRI. Session 3 comprised real tDCS for 5 consecu-
tive days followed by pain assessment and a third fMRI
3. The sham and real tDCS phases were separated by a
7- to 11-day washout period (mean 9.9 days). We chose
to perform real tDCS for 5 consecutive days because
previous studies in patients with FM have shown a
meaningful reduction in clinical pain using this protocol
[8, 9]. To limit carryover from real to sham tDCS, we
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did not use a randomized design [26]. All participants
were debriefed during a final follow-up visit. Patients
were also offered a clinical referral to an outpatient
clinic at our institution for continuation of care with
regular therapy for their symptoms.
Clinical pain outcomes
Clinical pain intensity was assessed as an “average” ex-
perience for the week before each assessment using a
visual analogue scale (VAS), with 0 being “no pain” and
10 being “worst possible pain.” Clinical pain was also
assessed using the short-form McGill Pain Questionnaire
[27], and affective state was measured using the Positive
and Negative Affect Schedule (PANAS) [28]. We were
missing McGill baseline pain data for one patient,
PANAS scores across all conditions for one patient, and
PANAS baseline-only scores for two patients. The clin-
ical results have been published previously [24] and are
provided in Additional file 1: Table S1. Differences in
clinical variables across conditions were assessed with
repeated-measures analysis of variance (ANOVA) using
IBM SPSS version 22 software (IBM, Armonk, NY,
USA). Significance was set at an α level of p < 0.05. The
changes in clinical pain scores used in neuroimaging ana-
lyses were calculated by subtraction of sham − baseline
VAS and real − sham VAS.
tDCS protocol
The tDCS protocol was carried out as described previ-
ously [29]. Briefly, for both sham and real tDCS sessions,
the anode electrode was placed on the scalp over the left
motor cortex and the cathode was positioned over the
right supraorbital cortex. Positions were determined in-
dividually using the 10–20 international system of elec-
troencephalogram electrode placement at C3 and FP2,
respectively. Electrodes were placed by the same opera-
tors (AFD and TDN) for all patients. Active stimulation
consisted of 2 mA of current applied continuously for
20 minutes. During sham tDCS, the current was applied
for 30 seconds at the beginning and end of the session.
Patients were blinded to type of treatment (i.e., real vs.
sham) they were receiving. This protocol is identical to
that used in previous studies of M1 tDCS in patients
with FM [8, 9].
Neuroimaging methods
Resting state fMRI sessions were performed on an
Ingenia 3.0 T system (Philips Medical Systems, Best, the
Netherlands) with a 15-channel receive head coil. Each
scan lasted 10 minutes, and parameters included a T2*-
weighted blood oxygen level–dependent (BOLD) echo-
planar imaging sequence [repetition time (TR) 2000 ms,
echo time (TE) 30 ms, flip angle 77 degrees, 30 slices,
voxel size 3.44 × 3.33 × 4.00 mm]. Physiological data
(cardiac and respiratory volume) were collected simul-
taneously. A high-resolution structural image was ac-
quired for normalization purposes (TR/TE 9.8/4.6 ms,
flip angle 8 degrees, 151 slices, voxel size 1 × 1 × 1 mm).
fMRI data were checked for quality and head motion
greater than 3 mm; no data were excluded. Resting state
fMRI data were preprocessed using SPM8 (http://www.
fil.ion.ucl.ac.uk/spm/software/spm8/) running on MATLAB
R2010a (MathWorks, Natick, MA, USA) and included
physiological artifact correction, slice timing correction,
realignment, coregistration, normalization to Montreal
Neurological Institute space, and smoothing (full width at
half maximum 8 mm).
Seed to whole-brain FC analyses were performed using
the Conn Toolbox [30]. Seeds were chosen on the basis
of the following criteria: (1) location under stimulating
anode (left precentral gyrus and left postcentral gyrus
[M1/primary somatosensory cortex (S1); WFU PickAtlas
(http://www.nitrc.org/projects/wfu_pickatlas)], (2) struc-
tural connectivity to left M1 and S1 [right pre- and post-
central gyri, bilateral ventral lateral (VL) and ventral
posterolateral (VPL) thalamus; WFU PickAtlas), and (3)
our previous tDCS studies (PAG [14]). The time series
for each seed region was extracted and white matter,
cerebrospinal fluid signal, and realignment parameters
were entered into the analysis as regressors of no
interest. A band-pass filter (0.008–0.09 Hz) was applied
to remove linear drift artifacts and high-frequency noise.
First-level analyses were performed by correlating the
time series from each seed region with the rest of the
voxels in the brain, creating seed to whole-brain Fisher-
transformed correlation maps. These maps were imported
into SPM8 for group-level analyses.
For prediction analyses, we performed seed to whole-
brain regression analyses with baseline FC maps and
change in clinical pain (real − baseline) as a regressor of
interest. Main effects were calculated using repeated-
measures ANOVA design with baseline, sham, and real
tDCS FC maps. The contrasts of interest were baseline
versus sham tDCS and sham versus real tDCS. We also
examined the change in FC across the entire study using
the contrast baseline versus real tDCS. To examine cor-
relations between changes in connectivity and changes
in clinical pain, we first created difference images by
subtracting first-level connectivity maps for each subject
(sham − baseline, real − sham, and real − baseline). We
then performed a regression analysis with VAS change
scores as a regressor of interest. All analyses were con-
trolled for differences in age. Results were thresholded at
uncorrected p < 0.001 on the voxel level and p < 0.05
familywise error (FWE) correction for multiple com-
parisons at the cluster level with a cluster size of greater
than 5 voxels. For a priori regions that did not meet this
stringent threshold, we performed small volume corrections
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(SVCs) using the anatomically (WFU PickAtlas) defined
regions of interest (ROIs) used as seed regions or func-
tionally defined ROIs derived from our previous findings
in FM [6]. Significance for SVC was set at p < 0.05 FWE at
the cluster level with a cluster size of greater than 5 voxels.
The Fisher-transformed correlation values were extracted
using MarsBaR software (http://marsbar.sourceforge.net/)
and post hoc analyses performed using IBM SPSS version
22 software.
Results
Clinical pain reduction with sham and real tDCS
As reported previously [24], there was a trend toward
improvement in VAS clinical pain during the sham
period [mean difference ± standard error (SE) for sham
minus baseline −1.042 ± 0.572, 95 % confidence interval
(CI) −0.218 to 2.301; p = 0.096], and there was no signifi-
cant difference in pain relief between sham and real tDCS
(mean difference ± SE for real minus sham −0.750 ± 0.494,
95 % CI −1.838 to 0.338; p = 0.157). However, clinical pain
significantly decreased across the entire study from
baseline to after real tDCS (mean difference ± SE for real
minus baseline −1.792 ± 0.762, 95 % CI −3.470 to −0.114;
p = 0.038). There were no significant differences in clinical
pain as measured by the McGill Pain questionnaire or
PANAS positive affect. There was a significant difference
between baseline and real tDCS in PANAS negative affect
(mean difference ± SE for real minus baseline −3.0 ± 1.067,
95 % CI −5.461 to −0.539; p = 0.023). Clinical results for
each patient individually across the study are presented in
Additional file 1: Table S2.
Stronger baseline FC is associated with subsequent
analgesia
To examine the common predictive ability of baseline
FC for reductions in pain across sham and real tDCS (as
this was where the significant clinical effect on pain was
found), we used predefined ROIs and correlated baseline
FC with improvements in clinical pain across the entire
study period (real − baseline). Patients who had stronger
connectivity at baseline between the left M1 seed and
left VL thalamus (p = 0.011 FWE, SVC), between the left
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Fig. 1 Stronger FC at baseline predicts analgesia. a Patients with higher L M1 (seed in white) − L VL (anatomical region outlined in black) connectivity
at baseline had a greater reduction in clinical pain across sham and real transcranial direct current stimulation (tDCS) periods (displayed at p = 0.005).
b Stronger L S1 (seed in white) − L anterior insula FC at baseline predicted a better clinical response. c Connectivity between the L VL thalamus (seed
in white) and the PAG at baseline also predicted patients who would respond to sham and real tDCS treatment. Data shown are Fisher-transformed
r values. M1 primary motor cortex, VL ventral lateral, S1 primary somatosensory cortex, PAG periaqueductal gray, VAS visual analogue scale, L left, R right,
FC functional connectivity
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S1 seed and left anterior insula (p = 0.001 FWE), and be-
tween the left VL thalamus seed and PAG (p = 0.007
FWE, SVC) had greater improvement in clinical pain
scores across sham and real tDCS periods (Fig. 1 and
Table 1). Importantly, these correlations were also sig-
nificant when we looked at change in clinical pain from
baseline to sham or from sham to real tDCS alone (with
one exception: left VL–PAG baseline FC and real–sham
clinical pain; p = 0.057) (Additional file 1: Table S3).
There were no regions that showed significant correla-
tions between less connectivity at baseline and better
treatment response (Additional file 1: Figure S2). In post
hoc analyses, there were no significant correlations
between baseline connectivity of these regions and the
change McGill clinical pain or the change in positive
and negative affect.
Sham tDCS is associated with decreases in FC
Because previous studies have shown a placebo analgesic
response on experimental and clinical pain during sham
tDCS [31], we examined whether sham tDCS changed
resting state FC (sham − baseline) (Table 2). After five
sessions of sham tDCS, patients with FM had reduced
FC between the left VPL thalamus seed and left S1
(p = 0.016 FWE), left amygdala/parahippocampal gyrus
(p = 0.004 FWE), and right inferior parietal lobule (IPL)
(p = 0.013 FWE) (Fig. 2a). FC also decreased between the
right VPL thalamus seed and left IPL (p = 0.049 FWE)
(Fig. 2b), between the PAG seed and precuneus (p = 0.001
FWE) (Fig. 2c), and between the right M1 seed and right
cerebellum (p = 0.002 FWE). There were no significant
increases in FC after sham compared with baseline
(Additional file 1: Figure S3).
To determine if changes in FC were related to changes
in clinical pain during the sham period, we ran a regression
analysis with each participant’s connectivity difference map
(sham − baseline) with change in VAS (sham − baseline) as
a regressor of interest (Table 3). The change in connectivity
between the left VL thalamus seed and the left posterior
insula was positively correlated with change in clinical
pain (p = 0.001 FWE). Patients with reduced connectivity
between the left VL thalamus and posterior insula had a
greater reduction in pain intensity after sham tDCS
(Fig. 3a). Reduced connectivity between the right VPL
thalamus seed and right M1 (p = 0.001 FWE), right S1
(p = 0.008 FWE), and left M1 (p = 0.046 FWE) also corre-
lated with reduced pain after sham tDCS (Fig. 3b). De-
creased FC between the right S1 seed and the cerebellum
(p = 0.001 FWE) was also positively correlated with change
in pain. These changes in connectivity were not signifi-
cantly correlated with changes in positive and negative
affect or McGill clinical pain. There were no significant
relationships between increases in connectivity and de-
creases in clinical pain (Additional file 1: Figure S6).
Real tDCS is also associated with decreases in FC
Next, we measured changes in FC between sham and real
tDCS (Table 4). After real tDCS, FC decreased between
the left VL thalamus seed and the medial prefrontal cortex
(mPFC) (p = 0.006 FWE) and left supplementary motor
area (SMA) (p = 0.043 FWE) (Fig. 4a). FC also decreased
between the right VL thalamus seed and the cerebellum
(p = 0.001 FWE) and left SMA (p = 0.016 FWE) (Fig. 4b).
There were no significant increases in FC (Additional
file 1: Figure S3).
When we compared baseline with real tDCS, we found
significant decreases in connectivity between the left VPL
thalamus seed and the left IPL (p = 0.041 FWE) and be-
tween the PAG seed and the posterior cingulate (p = 0.007
Table 1 Predicting changes in clinical pain from baseline
functional connectivity
Seed MNI coordinates
(x, y, z)
r Value T Cluster
size
Cluster
p valueFC region
L M1
L VL thalamus −18 −14 12 −0.938 5.41 7 0.011 FWE*
L S1
L anterior
insula
−42 14 2 −0.961 9.38 396 0.001 FWE
L VL thalamus
PAG −6 −26 −8 −0.929 5.25 8 0.007 FWE*
FC functional connectivity, L left, M1 primary motor cortex, VL ventral lateral,
S1 primary somatosensory cortex, PAG periaqueductal gray, MNI Montreal
Neurological Institute T test statistic
*Significant at p < 0.05 with small volume correction
Table 2 Main effect of sham tDCS on FC
Seed MNI coordinates
(x, y, z)
T Cluster
size
Cluster
p valueFC region
Baseline > sham
L VPL
L S1 −62 −16 42 6.80 304 0.016 FWE
L parahipp/amyg −32 −14 −26 6.70 408 0.004 FWE
R IPL 44 −36 32 5.69 320 0.013 FWE
R VPL
L IPL −34 −36 34 5.28 230 0.049 FWE
R M1 (precentral gyrus)
R cerebellum 16 −74 −36 5.91 485 0.002 FWE
PAG
Precuneus −20 −84 24 4.88 618 0.001 FWE
Baseline < sham
N.S.
tDCS transcranial direct current stimulation, FC functional connectivity, L left,
R right, VPL ventral posterolateral, S1 primary somatosensory cortex, parahipp/
amyg parahippocampal gyrus and amygdala, IPL inferior parietal lobule,
M1 primary motor cortex, PAG periaqueductal gray, N.S. not significant,
MNI Montreal Neurological Institute T test statistic
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FWE) (Additional file 1: Figure S4 and Table S4). There
were no significant increases in FC.
We did not find any regions that met whole-brain cor-
rection in a regression analysis measuring changes in
connectivity in relation to changes in pain after real
tDCS compared with sham. However, there were regions
that met significance using SVC with a priori ROIs
(Table 5). The change in connectivity between the left
VPL thalamus and left M1/S1 (p = 0.007 FWE, SVC) and
right posterior insula (p = 0.007 FWE, SVC) was posi-
tively correlated with the change in clinical pain (Fig. 5).
The change in left VL thalamus to right posterior insula
connectivity was also positively correlated with change
in pain (p = 0.022 FWE, SVC). Patients with reduced
connectivity between the VL/VPL thalamus and M1/S1
and posterior insula had a greater reduction in pain
intensity after real tDCS. In post hoc analyses, these
changes in connectivity were also correlated with the
change in McGill clinical pain (Additional file 1: Table S6).
However, there were no significant relationships between
FC and changes in positive or negative affect. In an
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Fig. 2 Sham transcranial direct current stimulation (tDCS) decreases FC compared with baseline. a Decreased connectivity between the left VPL
(seed in white) and left S1, left parahippocampal gyrus, and amygdala after sham tDCS compared with baseline. Plots show changes in FC from
baseline to after the sham treatment period for each patient with fibromyalgia. b Decreased connectivity between the right VPL (seed in white)
and left IPL. c Decreased connectivity between the PAG (seed in white) and precuneus. Data shown are Fisher-transformed r values. VPL ventral
posterolateral, S1 primary somatosensory cortex, parahipp parahippocampal gyrus, amyg amygdala, IPL inferior parietal lobule, PAG periaqueductal
gray, L left, R right, FC functional connectivity
Table 3 Correlations between change in FC and change in
clinical pain (VAS) for sham versus baseline
Seed MNI coordinates
(x, y, z)
r Value T Cluster
size
Cluster
p valueFC region
L VL thalamus
L posterior
insula
−48 −12 0 0.979 12.33 313 0.001 FWE
R VPL thalamus
R M1 56 −12 42 0.969 9.85 603 0.000 FWE
R S1 44 −34 54 0.917 7.46 235 0.008 FWE
L M1 −46 −6 26 0.936 9.41 158 0.046 FWE
R S1 (postcentral gyrus)
Cerebellum 36 −52 −20 0.937 7.63 355 0.001 FWE
FC functional connectivity, VAS visual analog scale, L left, R right, VL ventral
lateral, VPL ventral posterolateral, M1 primary motor cortex, S1 primary
somatosensory cortex, MNI Montreal Neurological Institute T test statistic
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analysis in which we examined changes in connectivity
and changes in clinical pain from baseline to real tDCS,
we found that patients with reduced connectivity between
left S1 and left SMA had a greater reduction in clinical
pain (p = 0.013 FWE) (Additional file 1: Figure S5 and
Table S5). Again, there were no significant relationships
between increases in connectivity and decreases in clinical
pain, neither between sham and real tDCS nor between
baseline and real tDCS (Additional file 1: Figure S6).
Discussion
This study shows, for the first time to our knowledge,
that a clinically relevant schedule of repetitive M1 tDCS
sessions alters FC in patients with FM. Real tDCS
(versus sham) reduced FC between the VL thalamus and
SMA, mPFC, and the cerebellum. These changes in FC
were distinct from those observed after sham tDCS.
Sham tDCS (compared with baseline) decreased con-
nectivity between the VPL thalamus and S1, IPL, and the
L VL thalamus seed
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Fig. 3 Correlations between changes in FC and changes in clinical pain after sham transcranial direct current stimulation (tDCS). a Decreased FC
between the left VL thalamus (seed in white) and left posterior insula was correlated with a reduction in clinical pain after sham tDCS. b Decreased FC
between the right VPL thalamus (seed in white) and left M1, right M1, and right S1 correlated with reduced clinical pain after sham tDCS. Data shown
are Fisher-transformed r values. VL ventral lateral, VPL ventral posterolateral, M1 primary motor cortex, S1 primary somatosensory cortex, VAS visual
analogue scale, L left, R right, FC functional connectivity
Table 4 Main effect of real tDCS on FC
Seed MNI coordinates
(x, y, z)
T Cluster
size
Cluster
p valueFC region
Sham > real
L VL thalamus
mPFC 4 56 8 5.66 362 0.006 FWE
L SMA −2 24 56 5.49 228 0.043 FWE
L OFG −10 40 −22 5.91 185 0.08 FWEa
R VL thalamus
Cerebellum 16 −46 −22 6.88 1122 0.000 FWE
L SMA −6 22 58 6.16 313 0.016 FWE
Sham < real
N.S.
tDCS transcranial direct current stimulation, FC functional connectivity, L left,
R right, VL ventral lateral, mPFC medial prefrontal cortex, SMA supplementary
motor area, OFG orbitofrontal gyrus, N.S. not significant, MNI Montreal
Neurological Institute T test statistic
aTrend at p < 0.05 familywise error correction for multiple comparisons
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parahippocampal gyrus/amygdala and between the PAG
and precuneus. However, after both sham and active
tDCS, we found a relationship between decreases in FC
among pronociceptive brain regions and reductions in
clinical pain. Patients with decreased connectivity be-
tween the VL thalamus and posterior insula and between
the VPL thalamus and M1/S1 had greater reductions in
clinical pain after sham and real tDCS. In addition, our
data indicate that patients with FM with stronger base-
line connectivity between left M1 and left VL thalamus,
between left S1 and left anterior insula, and between left
VL thalamus and PAG had a better analgesic response
across the entire study. Although we saw distinct main
effects for sham and active tDCS, the overlapping results
related to clinical changes in pain may point to a shared
placebo response in both sham and active conditions. A
summary of the results is depicted in Fig. 6.
Our findings are somewhat at odds with the existing
literature. For example, researchers in some studies have
reported increases in thalamic blood flow [32] or in-
creased M1–thalamus connectivity after M1 stimulation
[17, 33]. We suggest that these conflicting results can be
explained by the timing of stimulation and measure-
ment. In the other studies, neural activity was measured
during or immediately after M1 stimulation, which likely
has a different neural signature than after 1 week of re-
petitive stimulation. In support of this notion, García-
Larrea and colleagues noted that thalamic blood flow
reverted to baseline levels 30 minutes after M1 stimula-
tion stopped [32]. Therefore, the initial or acute changes
in thalamic activity may cause a cascade of other events
that are important for analgesia [34], leading to the dis-
tinct long-term changes that we observed.
How might M1 stimulation promote analgesia in pa-
tients with chronic pain? One hypothesis states that M1
stimulation suppresses pain perception directly by inhi-
biting activity in the lateral thalamus [35, 36]. Compared
with healthy control subjects, patients with FM have in-
creased activity in pain-processing structures during ex-
perimental pain and increased connectivity in ascending
pronociceptive pathways at rest (see [37] for a recent re-
view on neuroimaging findings in FM), although the
specific role of the thalamus in FM remains unclear.
Both increases and decreases in thalamic activity or con-
nectivity during experimental pain or at rest have been
reported [3, 4, 38, 39]. In the present study, we found
that strong M1–VL thalamus connectivity at baseline
predicted a greater reduction in pain across sham and
real tDCS periods. This is consistent with work in
central poststroke pain, where analgesic response to
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Fig. 4 Real transcranial direct current stimulation (tDCS) decreases FC compared with sham. a Decreased connectivity between the left VL (seed in white)
and SMA and mPFC after real tDCS. b Decreased connectivity between the right VL (seed in white) and SMA and cerebellum after real tDCS. Plots show
changes in FC between sham and real tDCS for each patient with fibromyalgia. Data shown are Fisher-transformed r values. OFG orbitofrontal gyrus,
VL ventral lateral, SMA supplementary motor area, mPFC medial prefrontal cortex, L left, R right, FC functional connectivity
Table 5 Correlations between change in FC and change in
clinical pain (VAS) for real versus sham
Seed MNI coordinates
(x, y, z)
r Value T Cluster
size
Cluster
p valueFC region
L VL thalamus
R posterior
insula
42 −24 20 0.887 5.08 5 0.022 FWEa
L VPL thalamus
L M1/S1 −48 −18 50 0.923 6.45 89 0.007 FWEa
R posterior
insula
46 −30 24 0.927 7.64 23 0.007 FWEa
FC functional connectivity, VAS visual analogue scale, L left, R right, VL ventral
lateral, VPL ventral posterolateral, M1 primary motor cortex, S1 primary
somatosensory cortex, MNI Montreal Neurological Institute T test statistic
aSignificant at p < 0.05 with small volume correction
Cummiford et al. Arthritis Research & Therapy  (2016) 18:40 Page 8 of 12
repetitive transcranial magnetic stimulation over M1 was
found to be best in patients with intact thalamocortical
tracts (as measured by diffusion tensor imaging) [22, 23].
Invasive MCS decreases thalamic hyperactivity [40], likely
by activating GABAergic divisions of the thalamus and in-
creasing inhibition [41]. In healthy rodents and in a rodent
model of neuropathic pain, MCS decreased the firing rate
of VPL thalamic neurons specifically [42, 43]. In a previ-
ous study of the same patients reported here, we found a
trend toward decreased Glx in the bilateral thalamus after
real tDCS compared with sham [24]. The decreases in FC
between the thalamus and SMA, mPFC, and cerebellum
after real tDCS in this study lends support to the hypoth-
esis that M1 stimulation disrupts thalamic activity.
Another hypothesis is that M1 stimulation causes
analgesia indirectly via the facilitation of descending
antinociceptive pathways and release of endogenous opi-
oids [34]. Maarrawi and colleagues hypothesized that
patients with neuropathic pain who have higher levels of
endogenous opioids at baseline would be least likely to
benefit from any additional opioid release caused by
MCS, and, indeed, patients with lower baseline binding
potential for an opioid agonist (reflecting either fewer
opioid receptors or higher levels of endogenous opioids)
in the thalamus, insula, and PAG were the least likely to
benefit from MCS [20]. The relationship between opi-
oids and BOLD fMRI signaling deserves further study,
but in healthy controls morphine administration de-
creases activity in S1, thalamus, and PAG [44] while
naloxone (an opioid antagonist) increases activity in S1,
thalamus, insula, and PAG [45]. In our study, stronger
M1–thalamus, S1–insula, and thalamus–PAG connec-
tivity at baseline predicted a better treatment response.
Because both sham and real tDCS also cause endogen-
ous opioid release [14], this finding may suggest that
patients with connectivity between regions under the
stimulating anode (M1/S1) and regions with a high
density of opioid receptors are the most likely to benefit
from tDCS. We also found decreases in FC in many of
these regions after sham and real tDCS, which could
also reflect opioid release.
Placebo analgesia is a well-documented psychobio-
logical event, and imaging studies have revealed overlap
between brain networks involved in pain processing and
those implicated in the placebo response [46, 47]. The
decreases in FC found after sham (compared with
baseline) are consistent with previous studies of placebo
analgesia showing decreased activity in the thalamus, S1,
amygdala, and insula [48–50]. Importantly, the similarity
of FC results related to changes in clinical pain between
baseline and sham and between sham and real sessions
may suggest a shared placebo component across condi-
tions. However, the changes in FC after the sham period
in this study cannot be interpreted solely as a placebo ef-
fect, because we lacked a control group that received no
treatment for comparison. Therefore, any changes from
baseline to sham could also reflect regression to the
mean or the natural course of the disease [51]. Regres-
sion to the mean also may account for a portion of the
change in clinical pain after both the sham and real
tDCS periods.
Our study was limited by the small sample size, which
may have contributed to the lack of a significant clinical
effect between sham and active conditions and reduced
statistical power. In this pilot study, we did not aim to
validate the efficacy of M1 tDCS as a treatment for FM;
rather, our goal was to determine if a clinically relevant
schedule of tDCS sessions altered resting state FC in
patients with FM. However, as with most pain treat-
ments wherein only a portion have a clinically meaning-
ful response, half of the patients in the present study did
report a drop in pain on the VAS (active − sham), and
this change was correlated with reductions in thalamo-
cortical connectivity. This study is significantly limited
Fig. 5 Correlation between change in FC and change in clinical pain after real transcranial direct current stimulation (tDCS). Patients with reduced
FC between the L VPL thalamus (seed in white) and left S1/M1 and right posterior insula had greater reductions in clinical pain after real tDCS
compared with sham (displayed at p = 0.005). Data shown are Fisher-transformed r values. VPL ventral posterolateral, S1 primary somatosensory
cortex, M1 primary motor cortex, VAS visual analogue scale, L left, R right, FC functional connectivity
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by the lack of counterbalancing between sham and active
conditions. Therefore, we cannot rule out carryover
effects from the sham period. However, sham and active
phases were separated by a washout period of at least
1 week, so we find this unlikely. Another limitation is
that the stimulation sessions were single-blinded. Finally,
research has shown that stimulation for 30 seconds at
the beginning and end of the sham condition can mimic
the sensation during active treatment and that patients
cannot differentiate between sham and real stimulation
at 1 mA [52]. However, the credibility of sham tDCS and
the effectiveness of patient blinding at 2 mA has recently
been questioned [11]. Given our repeated-measures
design, it is likely that the patients became aware of the
condition differences. Our results should be interpreted
with caution, and additional studies designed to replicate
our findings are needed.
Conclusions
Our results support the hypothesis that repetitive M1
tDCS causes lasting changes in FC and may relieve pain
by altering thalamic activity. Analgesia may result from
the inhibition of thalamic activity and subsequent de-
creases in FC, both of which could be caused by the re-
lease of endogenous opioids. Future studies that combine
fMRI and positron emission tomography within the same
patients after repetitive M1 tDCS are needed to test this
hypothesis. It is possible that there is a significant placebo
component common to both sham and real tDCS. Future
studies should include a no-treatment control group to
test this hypothesis. It remains to be seen if similar
changes in FC are observed for tDCS in other chronic
pain conditions.
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